MehdiShahidiMD

PubMed

• 237 citations
  Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
  James Chih-Hsin Yang, Vera Hirsh, Martin Schuler, Nobuyuki Yamamoto, Kenneth J. O'Byrne, Tony Mok, Victoria Zazulina, Mehdi Shahidi, Juliane Lungershausen, Dan Massey,...> ;Journal of Clinical Oncology. 2013 Sep 20
• 269 citations
  LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
  Nobuyuki Katakami, Shinji Atagi, Koichi Goto, Toyoaki Hida, Takeshi Horai, Akira Inoue, Yukito Ichinose, Kunihiko Koboyashi, Koji Takeda, Katsuyuki Kiura, Kazuto Nishi...> ;Journal of Clinical Oncology. 2013 Sep 20
• 2417 citations
  Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
  Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer...> ;Journal of Clinical Oncology. 2013 Sep 20
• Diethylstilbestrol in castration-resistant prostate cancer.
  Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, Horwich A, Dearnaley D> ;BJU Int.. 2012-12-01
• Feasibility of Conjunctival Hemodynamic Measurements in Rabbits: Reproducibility, Validity and Response to Acute Hypotension.
  Gaynes, B., Teng, P. Y., Wanek, J., Shahidi, M.> ;Microcirculation. 2012 Aug
• 9 citations
  Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes
  Xue Song, Helen Varker, Michel Eichelbaum, Peter Stopfer, Mehdi Shahidi, Kathleen L. Wilson, Rolf Kaiser, Henrik W. Finnern> ;Lung Cancer. 2011 Oct 1
• A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.
  Eisenstat DD, Nabors LB, Mason WP, Perry JR, Shapiro WR, Kavan P, Phuphanich S, Fu Y, Cong XJ, Shahidi M, Reardon DA> ;J. Clin. Oncol.. 2011-05-20
• A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).
  Yamamoto N, Katakami N, Atagi S, Hida T, Goto K, Horai T, Inoue A, Ichinose Y, Kobayashi K, Takeda K, Kiura K, Saka H, Tamura T, Okamoto I, Nogami N, Morinaga R, Nishi...> ;J. Clin. Oncol.. 2011-05-20
• Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
  Janjigian YY, Groen HJ, Horn L, Smit EF, Fu Y, Wang F, Shahidi M, Denis LJ, Pao W, Miller VA> ;J. Clin. Oncol.. 2011-05-20
• 276 citations
  Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
  Timothy A. Yap, Laura Vidal, Jan Adam, Peter Stephens, James Spicer, Heather Shaw, J.E. Ang, Graham Temple, Sue E. Bell, Mehdi Shahidi, Martina Uttenreuther-Fischer, P...> ;Journal of Clinical Oncology. 2010 Sep 1
• Quantitative assessment of conjunctival microvascular circulation of the human eye.
  Shahidi, M.,Wanek, J.,Gaynes, B.,Wu, T.> ;Microvasc. Res.. 2010 Jan 08
• A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel.
  Ang J, Mikropoulos C, Stavridi F, Rudman S, Uttenreuther-Fisher M, Shahidi M, Pemberton K, Wind S, de Bono J, Spicer JF> ;J. Clin. Oncol.. 2009-05-20
• A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR...
  Shih J, Yang C, Su W, Hsia T, Tsai C, Chen Y, Chang H, Terlizzi E, Shahidi M, Miller VA> ;J. Clin. Oncol.. 2009-05-20
• Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in p...
  Yang C, Hirsh V, Cadranel J, Chen Y, Park K, Kim S, Chao T, Oberdick M, Shahidi M, Miller V> ;J. Clin. Oncol.. 2009-05-20
• Pharmacokinetics (PK) of [14C]-BIBW 2992 after administration of a single dose of 15 mg [14C]-BIBW 2992 oral solution in healthy male volunteers.
  Stopfer P, Narjes H, Gaschler-Markefski B, Gansser D, Shahidi M> ;J. Clin. Oncol.. 2008-05-20
• Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary resul...
  Yang C, Shih J, Chao T, Tsai C, Yu C, Yang P, Streit M, Shahidi M, Miller VA> ;J. Clin. Oncol.. 2008-05-20
• 41 citations
  Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma.
  Young K Lee, Gary Cook, M. A. Flower, Carl G Rowbottom, Mehdi Shahidi, Bhupinder Sharma, Steve Webb> ;Radiotherapy and Oncology. 2004 Dec 1
• Cardiovascular disease as a long-term complication of treatment for testicular cancer.
  Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP> ;J. Clin. Oncol.. 2003-04-15
• Radiotherapy for rectal cancer.
  Paul G S Cornes, Mehdi Shahidi> ;The New England Journal of Medicine. 2002 Jan 10
• Radiation endocrine action in prostate cancer.
  Cornes PG, Shahidi M> ;J. Clin. Oncol.. 2000-12-01
• Delay in starting treatment for tuberculosis in east London.
  Lewis, K. E., Stephens, C., Shahidi, M. M., Packe, G.> ;Commun Dis Public Health. 2003 Jun
• Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management.
  Shahidi, M., Norman, A. R., Dearnaley, D. P., Nicholls, J., Horwich, A., Huddart, R. A.> ;Cancer. 2002 Aug 1
• Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer.
  Murthy, V., Norman, A. R., Shahidi, M., Parker, C. C., Horwich, A., Huddart, R. A., Bange, A., Dearnaley, D. P.> ;BJU Int. 2006 Mar
• Site of relapse after chemotherapy alone for stage I and II Hodgkin''s disease.
  Shahidi, M., Kamangari, N., Ashley, S., Cunningham, D., Horwich, A.> ;Radiother Oncol. 2006 Jan
• Join now to see all